Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for FLUTEMETAMOL F-18
- Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy
- 18F-Flutemetamol and Plaque Vulnerability
- A Proof of Concept Study of the Prevention of Mild Cognitive Impairment and Eventual Alzheimer's Disease Using F18 Flutemetamol
- Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.
- Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging
- Comparison of PET Amyloid Imaging in Japanese and Western Subjects
- Implications for Management of PET Amyloid Classification Technology
- Investigating the Clinical Consequences of Flutemetamol-PET-scanning
- Amyloid Plaque Deposition in Chemotherapy-Induced Cognitive Impairment
- Longitudinal Study of Brain Amyloid imaGing in MEMENTO
- An Efficacy and Safety Trial of Verubecestat (MK-8931) in Mild to Moderate Alzheimer's Disease (P07738)
- Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images
- Bridging Study of C11 Pittsburgh Compound B (PiB) and F18 Flutemetamol Brain Positron Emission Tomography (PET)
- Positron Emission Tomography (PET) Amyloid Imaging of the Brain in Healthy Young Adult Subjects
- Practice Effects and Amyloid Imaging Using 18F-PIB or Flutemetamol PET and FDG-PET
- Positron Emission Tomography (PET) Imaging of Brain Amyloid Compared to Post-Mortem Levels
- Positron Emission Tomography Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
- PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
- Assess the Prognostic Usefulness of Flutemetamol (18F) Injection for Identifying Subjects With Amnestic Mild Cognitive Impairment Who Will Convert to Clinically Probable Alzheimer's Disease
Clinical trials list
click for details